Multiple sclerosis progresses at vastly different rates from person to person, but large studies give us useful averages. Without treatment, more than half of people with relapsing-remitting MS (the most common form) transition to a steadily worsening phase within 10 years, and about 90% do so within 25 years. With modern treatment, those timelines have stretched considerably, and MS is increasingly managed as a chronic lifelong condition rather than one that leads to rapid disability.
The Two Phases of Progression
Most people (roughly 85%) are diagnosed with relapsing-remitting MS, where symptoms flare up and then partially or fully resolve. Over time, many of these patients shift into a second phase called secondary progressive MS, where disability accumulates gradually between or even without relapses. Natural history studies from the pre-treatment era found that between one-third and one-half of patients developed this progressive phase after 15 to 20 years. Earlier data placed the timeline even shorter, with over 50% converting within a decade when untreated.
A smaller group, about 10 to 15% of people with MS, is diagnosed with primary progressive MS from the start. In this form there are no clear relapses. Disability builds steadily from the beginning, typically affecting walking ability first. Primary progressive MS tends to be diagnosed later in life and generally accumulates disability faster than the relapsing-remitting form.
What Disability Looks Like Over Time
Neurologists track MS progression using a disability scale that runs from 0 (normal exam) to 10. The lower end of the scale reflects neurological findings that may not affect daily life much, like a numb patch or mild imbalance. Once the score reaches about 4.0, walking limitations become noticeable. A score of 6.0 means needing a cane or similar aid to walk. In one 10-year study of newly diagnosed relapsing-remitting patients, 43% reached that 4.0 threshold during follow-up, and about 22% converted to secondary progressive MS.
These numbers reflect averages. Some people live decades with minimal disability. Others reach significant walking difficulty within a few years. The individual range is enormous, which is why researchers have focused heavily on identifying what predicts a faster or slower course.
Factors That Speed Up or Slow Down Progression
Age at Diagnosis
Age is one of the strongest predictors. People diagnosed after age 50 (late-onset MS) tend to accumulate disability significantly faster than those diagnosed in their 20s or 30s. In one study comparing the two groups, late-onset patients had a median disability score of 4.5 at their last visit, compared to 2.5 for early-onset patients. Their disease severity scores also worsened over time, while severity in the younger group stayed relatively stable. Researchers attribute this to the aging brain’s reduced ability to repair damage and a greater tendency toward the progressive, neurodegenerative component of the disease rather than the inflammatory, relapsing component.
Lesion Burden and Brain Volume
The total volume of lesions visible on MRI turns out to be a powerful predictor of future disability. It acts as a kind of bottleneck: other markers of disease activity, like nerve fiber damage and loss of gray matter, funnel their effects through overall lesion load. People who show significant gray matter shrinkage early in the disease tend to progress faster over the next several years. A brain that has already lost substantial volume has less reserve to compensate for new damage.
Smoldering Inflammation
Even when relapses stop, MS can continue to worsen through a process sometimes called smoldering neuroinflammation. This involves chronic active lesions, areas of damage where immune cells at the edges keep slowly expanding and destroying nearby nerve fibers. These lesions are particularly destructive because they impair the brain’s ability to repair itself and cause ongoing nerve degeneration that radiates outward from the original damage site.
The number of chronic active lesions a person has correlates with faster disability accumulation. In prospective studies, patients with more than four of these lesions at baseline showed measurable worsening within just two years. These lesions are present across all forms of MS and are largely resistant to current treatments, which is why disability can worsen even in people whose relapses are well controlled.
Progression Without Relapses
One of the more important findings in recent MS research is that disability can accumulate completely independently of relapses. This phenomenon, called progression independent of relapse activity, means the disease is worsening through slow neurodegeneration rather than acute inflammatory attacks. In a large Canadian study of over 800 patients with early MS, about 3.5 to 3.75% experienced this type of silent progression regardless of which treatment they were on. The rates were strikingly consistent across different medications.
People who experienced this silent progression tended to be female, older at disease onset, and had longer disease duration. This finding helps explain why some patients feel they are getting worse even when their MRI looks stable and they haven’t had a relapse in years. The smoldering, neurodegenerative component of MS can operate beneath the threshold of what standard monitoring catches.
How Treatment Changes the Timeline
Modern disease-modifying therapies have meaningfully altered MS progression for most patients. People treated today experience fewer relapses and live longer than those in earlier decades. Global MS mortality rates dropped from 0.17 per 100,000 in 1990 to 0.13 per 100,000 in 2021, and projections suggest they will continue falling through 2035. One long-term Canadian study found that patients treated with one of the earlier injectable therapies had roughly 30% lower mortality compared to untreated patients.
Starting a highly effective therapy early in the disease appears to reduce the long-term economic and functional impact of MS, including a 40% lower likelihood of needing supported employment compared to starting a moderate-efficacy treatment. However, no current therapy fully prevents the transition to a progressive phase. Treatment mainly targets the inflammatory component of MS, the relapses and new lesion formation, while the smoldering neurodegenerative process remains harder to control.
A Realistic Picture
If you were diagnosed recently, the statistics from the 1980s and 1990s that dominate many online sources paint a grimmer picture than what most patients experience today. The 50%-converting-within-10-years figure comes from an era before effective treatments existed. Current outcomes are substantially better, though they vary widely based on your age, how much damage is already present, and how your disease responds to treatment.
The most useful way to think about MS progression is not as a single predictable timeline but as a disease with two overlapping engines: acute inflammation (relapses) and slow-burning neurodegeneration. Treatments are good at suppressing the first engine and less effective against the second. How fast your MS progresses depends largely on the balance between those two processes, something your neurologist can estimate over time through MRI monitoring, clinical exams, and tracking subtle changes in cognition and walking speed.